Circio Holding (LSE:0RIS) - Aandelenkoers, Nieuws & Analyse

0RIS Overzicht aandelen

A biotechnology company, develops novel circular RNA and immunotherapy medicines. Meer informatie

0RIS fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 86.5% per jaar groeien

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( NOK56M )

Heeft een omzet van minder dan 1 miljoen USD ( NOK10M )

Negatief eigen vermogen

Aandelen zijn zeer illiquide

+ 2 meer risico's

Circio Holding ASA Concurrenten

Theracryf

AIM:TCF

UK£2.3m

BSF Enterprise

LSE:BSFA

UK£3.4m

Genflow Biosciences

LSE:GENF

UK£6.3m

Verici Dx

AIM:VRCI

UK£8.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Circio Holding
Historische aandelenkoersen
Huidige aandelenkoers	NOK 11.20
52 Week Hoogtepunt	NOK 37.20
52 Week Laag	NOK 11.12
Bèta	2.06
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	-96.14%
5 jaar verandering	-95.71%
Verandering sinds IPO	-96.27%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	0RIS	GB Biotechs	GB Markt
7D	0%	-6.0%	-0.3%
1Y	n/a	-22.4%	6.1%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe 0RIS presteerde ten opzichte van de UK Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe 0RIS presteerde ten opzichte van de UK markt.

Prijsvolatiliteit

Is 0RIS's price volatile compared to industry and market?
0RIS volatility
0RIS Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.5%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: 0RIS heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 0RIS in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2010	17	Erik Wiklund	www.circio.com

Circio Holding ASA Samenvatting

Hoe verhouden de winst en inkomsten van Circio Holding zich tot de beurswaarde?
0RIS fundamentele statistieken
Marktkapitalisatie	NOK 56.45m
Inkomsten(TTM)	-NOK 449.26m
Inkomsten(TTM)	NOK 10.00m

5.6x

P/S-verhouding

-0.1x

Koers/Winstverhouding

Is 0RIS overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
0RIS resultatenrekening (TTM)
Inkomsten	NOK 10.00m
Kosten van inkomsten	NOK 0
Brutowinst	NOK 10.00m
Overige uitgaven	NOK 459.26m
Inkomsten	-NOK 449.26m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

Feb 15, 2024

Winst per aandeel (EPS)	-62.71
Brutomarge	100.00%
Nettowinstmarge	-4,491.69%
Schuld/Eigen Vermogen Verhouding	-135.9%

Hoe presteerde 0RIS op de lange termijn?

Bekijk historische prestaties en vergelijking

0RIS Overzicht aandelen

Beloningen

Risicoanalyse

Circio Holding ASA Concurrenten

AIM:TCF

UK£2.3m

LSE:BSFA

UK£3.4m

LSE:GENF

UK£6.3m

AIM:VRCI

UK£8.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Circio Holding ASA Presents Circvec Circular RNA in Vivo Expression Proof-Of-Concept Data At ESGCT 2024 Annual Meeting

Circio Announces Strengthened in Vivo Data and Enhanced Circvec 2.2 Design

Circio Holding ASA has filed a Follow-on Equity Offering in the amount of NOK 60 million.

Circio Announces in Vivo Proof-Of-Concept for Its circVec circular RNA Platform Technology and Reinforced Gene Therapy Focus

Circio Holding ASA Announces Dosing of First Patient in the Collaborative Phase 2 Trial Sponsored by Georgetown University

Circio Holding ASA, Annual General Meeting, Jun 05, 2024

Recent updates

Circio Holding ASA Presents Circvec Circular RNA in Vivo Expression Proof-Of-Concept Data At ESGCT 2024 Annual Meeting

Circio Announces Strengthened in Vivo Data and Enhanced Circvec 2.2 Design

Circio Holding ASA has filed a Follow-on Equity Offering in the amount of NOK 60 million.

Circio Announces in Vivo Proof-Of-Concept for Its circVec circular RNA Platform Technology and Reinforced Gene Therapy Focus

Circio Holding ASA Announces Dosing of First Patient in the Collaborative Phase 2 Trial Sponsored by Georgetown University

Circio Holding ASA, Annual General Meeting, Jun 05, 2024

IOVaxis Therapeutics Files Updated TG01 Investigational New Drug Application with the Chinese National Medical Products Administration

Circio Holding ASA Announces Completion of Planned Safety Review and Opening for Full Enrollment of TG01 Study At Oslo University Hospital

New major risk - Financial position

High number of new directors

New major risk - Negative shareholders equity

High number of new directors

High number of new directors

Forecast to breakeven in 2024

High number of new directors

High number of new directors

Targovax Announces That the TG01 Study in Multiple Myeloma At Oslo University Hospital Has Received Regulatory Approvals to Proceed

Targovax ASA to Report Q4, 2023 Results on Feb 15, 2024

No longer forecast to breakeven

High number of new directors

Targovax ASA Completes ONCOS-102 Phase 1b Study in PD-1 CPI Resistant Advanced Melanoma Has Been Published in the Oncology Journal Clinical Cancer Research

No longer forecast to breakeven

High number of new directors

Targovax ASA Receives Approval to Proceed with the Oncos-102 Phase 2 Melanoma Study from the US FDA

No longer forecast to breakeven

High number of new directors

High number of new directors

Targovax ASA Announces that the FDA Grant Authorization to Initiate Clinical Trials with the Enhanced TG01 RAS Vaccine in the USA

High number of new directors

Targovax ASA Announces Board Changes

High number of new directors

Targovax ASA Appoints Lubor Gaal as Chief Financial Officer, Effective March 7, 2022

Targovax ASA Announces ONCOS-102 Achieves 25.0 Months Median Overall Survival in First Line Mesothelioma

Chief Executive Officer recently bought kr201k worth of stock

High number of new directors

High number of new directors

Chief Financial Officer Torbjørn Furuseth has left the company

High number of new directors

Targovax Receives Fast Track Designation for Oncos-102 in Melanoma

Targovax Announces Completed Enrollment in the Phase 1/2 Trial with ONCOS-102 in Combination with Durvalumab in Patients with Advanced Colorectal Cancer with Peritoneal Malignancies

Targovax ASA's ONCOS-102 Mesothelioma 24-Month Data Shows Class-Leading Median Overall Survival

Targovax ASA Announces Board Changes

Targovax Granted US Patent for Oncos-102 in Combination with Checkpoint Inhibitors

Continued Survival Benefit in Targovax's ONCOS-102 Trial in Mesothelioma At the 21-Month Follow-Up

Targovax ASA Receives Fast-Track Designation for ONCOS-102

Targovax ASA and Papyrus Therapeutics Enter Research Collaboration to Develop Novel ONCOS Viruses with Receptor Tyrosine Kinase (RTK) Inhibitor Functionality

Targovax grants IOVaxis 3 months extension to the exclusive license option for TG mutant RAS vaccines in Greater China and Singapore

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Circio Holding ASA Samenvatting

5.6x

-0.1x

Inkomsten en omzet